FDA MedWatch - Abrams Royal Pharmacy Sterile Products - Recall - Lack of Sterility Assurance

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: FDA MedWatch - Abrams Royal Pharmacy Sterile Products - Recall - Lack of Sterility Assurance
MedWatch logoMedWatch - The FDA Safety Information and Adverse Event Reporting Program

Abrams Royal Pharmacy Sterile Products - Recall - Lack of Sterility Assurance

AUDIENCE: Pharmacy, Consumer

ISSUE:  Abrams Royal Pharmacy is voluntarily recalling all unexpired lots of sterile products dispensed nationwide due to concerns of lack of sterility assurance. All unexpired lots of sterile compounded products are subject to the recall. Sterile products are injectable medications, IVs, eye drops, pellet implants, nasal sprays, inhalation solutions, and eye ointments.

The recall was issued after a single, isolated report of an adverse event involving a patient in California who received a compounded medication from the pharmacy. Out of an abundance of caution, Abrams Royal is voluntarily recalling all sterile products within expiry. If there is microbial contamination in products intended to be sterile, patients are at risk for serious, potentially life-threatening infections.

All recalled products have a label that includes Abrams Royal Pharmacy’s name and phone as well as a lot number. While not every label contains an expiration date, consumers can call the pharmacy with the lot number and find out the expiration date.

BACKGROUND: The recalled products were distributed to health care facilities, physicians, and patients from June 17, 2013, through December 17, 2013.

RECOMMENDATION: Abrams Royal Pharmacy is notifying its customers by mail and is arranging for the return of all recalled medication. To return product or request assistance related to this recall, users should contact Abrams Royal at 214-349-8000, Monday through Friday, between 9:00 a.m. and 5:00 p.m. CST.

Customers that have product which is being recalled should stop using it and contact the pharmacy to arrange for return of unused product.

Read the MedWatch safety alert, including a link to the firm Press Release, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm379383.htm


This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery

[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux